Patent Settlements: FTC Gets Teva To Eschew 'No-Authorized Generic' Deals
Executive Summary
Global settlement resolves charges against Teva in three pending FTC antitrust suits and expands terms of 2015 consent decree.
You may also be interested in...
Teva Slapped With €60m Fine Over Unlawful EU Provigil Delay
Teva received a “package of commercial side-deals” for agreeing to halt generic competition to Cephalon’s Provigil (modafinil) throughout the EU, which it “would not have achieved without committing to staying out of the market,” according to findings by the European Commission.
FTC Claims Revived Over Teva-AbbVie 'Pay For Delay' Deal
AbbVie and FTC both see wins and setbacks in Third Circuit ruling on case involving reverse-payment patent settlement with Teva.
AndroGel $448M Pay-For-Delay Disgorgement Spiked On Appeal, But Some Of FTC Complaint Resurrected
AbbVie and FTC both see wins and setbacks in Third Circuit ruling on case involving reverse-payment patent settlement with Teva.